Gemifloxacin for community-acquired pneumonia

Expert Opinion on Investigational Drugs

Volumn 17, Issue 5, 2008, Pages 779-786

  Lode, Hartmut M ^a,b   Schmidt Ionas, Malina ^c   Stahlmann, Ralf ^b  

^a RCMS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Institute of Pathology   (Germany)

Author keywords

CAP; Efficacy; Gemifloxacin; Tolerance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINAFLOXACIN; CONTRACEPTIVE AGENT; COTRIMOXAZOLE; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; ANTIINFECTIVE AGENT; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; LOOSE FECES; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MEASLES LIKE RASH; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; QT INTERVAL; RASH; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER ABDOMINAL PAIN; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; MICROBIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; PNEUMONIA, BACTERIAL;

EID: 44449085037     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.5.779     Document Type: Article

References (31)

1. File TM. Community-acquired pneumonia. Lancer 2003;362:1991-2001
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
3. ATS/IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
4. Hoban DJ, Doern GV, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniac, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):81-93
5. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN; The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infections to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46
6. Ferrara AL. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005;33:106-14
7. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
8. Lode HM. Managing community-acquired pneumonia: a European perspective. Respir Med 2007;101:1864-73
9. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60
10. File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004;39(Suppl 3):159-64
11. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-9
12. Anderson KB, Tan JS, File TM Jr, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-81
13. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal respiratory tract infections. Eur Respir J 2002;20(Suppl 36):3-8
14. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: In vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005;25:717-40
15. Brenwald NP, Appelbaum P, Davies T, Gill MJ. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Clin Microbial Infect 2003;9:140-3
16. Morrissey I, George JT. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother 2000;45(Suppl S1): 101-6
17. Heaton VJ, Ambler JE, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 2000;44:3112-17
18. Jones RN, Pfaller MA, Erwin ME. Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas. Inc J An microb Agents 2000;15:227-30
19. Koeth LM, Jacobs MR, Bajaksouzian S, et al. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. Int J Antimicrob Agents 2002;19:33-7
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: document M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute; 2005
21. Lowe MN, Lamb HM. Gemifloxacin. Drugs 2000;59:1137-47
22. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86
23. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17:529-43
24. Owens RC Jr, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005;51:45-9
25. Ball P, File TM, Twynholm M, Henkel T; the 061 Study Group. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001;18:19-27
26. File TM Jr, Schlemmer B, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001;48:67-74
27. Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002;24:1915-36
28. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20
29. File TM, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007;60:112-20
30. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005;65:949-91
31. Ball P, Mandell L, Patou G, et al. A respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004;13:421-9